Myriocin and D-PDMP Ameliorate Atherosclerosis in ApoE ≪sup>-/-</sup> Mice Via Reducing Lipid Uptake and Vascular Inflammation

Zemou Yu,Qing Peng,Songyue Li,Hong-Jun Hao,Jianwen Deng,Ling‐bing Meng,Zhiyuan` Shen,Weiwei Yu,Nan Ding,Yu Bai,Yining Huang

DOI: https://doi.org/10.2139/ssrn.3463243

2019-01-01

SSRN Electronic Journal

Abstract:Objective: Sphingolipids have been implicated in the etiology of atherosclerosis. The commonly used sphingolipid inhibitors, myriocin (a ceramide inhibitor) and D-PDMP (a glycosphingolipid inhibitor), have shown therapeutic potential but their efficacy and their underlying mechanisms remain unclear. We thus aimed to elucidate these mechanisms.Approach and Results: Here, ApoE-/- mice were fed a high-fat diet and treated with a control, myriocin, D-PDMP, or atorvastatin for 12 weeks. We analyzed the effects of these drugs on the size and detailed composition of atherosclerotic plaques. Molecular biological approaches were used to explore how the inhibitors affect lipid metabolism and foam-cell formation. Treatment with myriocin or D-PDMP led to smaller and less vulnerable atherosclerotic lesions and was almost as effective as atorvastatin. Sphingolipid inhibitors downregulated the expression of MCP-1 and its receptor CCR2, which play a key role in monocyte recruitment. They also decreased pro-inflammatory Ly-6chigh monocytes and influenced the uptake of modified LDL by downregulating the expression of CD36 and LOX-1. The inhibitors exhibited the advantage of maintaining normal glucose homeostasis compared with atorvastatin.Conclusions: These findings reveal for the first time that the modulation of sphingolipid synthesis can effectively alleviate atherosclerosis progression by preventing lipid uptake and reducing inflammatory responses in the arterial walls.Funding Statement: This work was supported by the Fundamental Research Funds for the Central Universities, Peking University Medicine Seed Fund for Interdisciplinary Research [grant number BMU2017MC005] and Funds for National Science and Technology Major Project [grant number 2012ZX09303-005-003].Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: All animal experiment protocols were approved by the Animal Care and Use Committee of the Peking University First Hospital (J201818) and performed in accordance with all relevant ethical regulations.